Shilpa Medicare’s arm gets CEP from EDQM for API Octreotide

18 Nov 2024 Evaluate

Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide.

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.

Octreotide is second peptide molecule in Shilpa’ s peptide portfolio. The CEP showcases its expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

292.90 -1.30 (-0.44%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×